{"id":"second-line-antipsychotics","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"5-20%","effect":"Dyslipidemia"},{"rate":"5-15%","effect":"Metabolic syndrome"}]},"_chembl":{"chemblId":"CHEMBL5858588","moleculeType":null,"molecularWeight":"430.62"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They achieve this by selectively binding to D2 receptors, which are involved in the regulation of movement and emotion. This blockade helps to alleviate symptoms of schizophrenia and other psychotic disorders.","oneSentence":"Second-line antipsychotics work by blocking dopamine receptors in the brain, reducing psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:42.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"},{"name":"Treatment of bipolar disorder"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05958875","phase":"PHASE4","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-01","conditions":"Schizophrenia and Related Disorders, Early Treatment-Resistance","enrollment":418},{"nctId":"NCT04996433","phase":"NA","title":"A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients","status":"RECRUITING","sponsor":"University of Greifswald","startDate":"2021-12-01","conditions":"Persistent Depressive Disorder, Treatment-resistant Depression","enrollment":396},{"nctId":"NCT00585273","phase":"","title":"Antipsychotics and Blood Vessel Function","status":"COMPLETED","sponsor":"Jess G. Fiedorowicz","startDate":"2007-09","conditions":"Bipolar Disorder, Schizophrenia","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":117,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Second-line Antipsychotics","genericName":"Second-line Antipsychotics","companyName":"Dr. Inge Winter","companyId":"dr-inge-winter","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Second-line antipsychotics work by blocking dopamine receptors in the brain, reducing psychotic symptoms. Used for Treatment of schizophrenia, Treatment of bipolar disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}